Tatva Chintan Pharma Chem Ltd

The transcript from the earnings call does not mention any current or planned fundraising through debt or equity. Key points related to finance and capex are: - Recent capex of approximately INR 100 crore invested in new plants and capacity expansions, primarily for operational optimization rather than capacity increase. - No mention of raising funds via debt or equity for these investments; internal funding or existing resources likely used. - Focus on commercializing new products and expanding existing plants, with Jolva plant commissioning expected around Sep-Oct 2027 to boost revenues. - Management did not indicate any intention or plan for new fundraising rounds during the call. Hence, as per the available information, there is no announced or planned debt or equity fundraising in the near term.

- New plant at Jolva: Greenfield project with planned capex of INR 250-275 crores, expected execution within 18 months starting Q1 2026; aimed at commercializing new agro intermediate products and expanding existing ones. - Dahej plant: Recent capex of ~INR 100 crores focused mostly on utilization expansion, optimization, and operational excellence rather than capacity increase. - Jolva plant expected commissioning: Around September-October 2027, adding new products and revenue streams. - Semiconductor Chemicals segment: Preparation for new plant progressing; first plant trial orders underway with gradual path to full commercialization. - Capital investment aimed at increasing operational flexibility, scalability, and profitability in agrochemicals, semiconductor chemicals, and existing plants over the next 1-2 years.

- Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products. - New Jolva plant targeting new agro products and expansion, contributing significantly from late 2027. - Pharma & Agro new intermediates (3 each) expected to contribute INR 200-250 crores additional revenue in calendar year 2027, ramping up from current sales base. - SDA segment projected to grow 25-30% in 2026 with capacity utilization around 55%, driven by Euro 7 norm demand surge starting 2027. - Semiconductor chemicals expected to reach full commercialization around 2028 with very large volume potential. - Electrolyte products, starting from a low base, projected to contribute about 7-8% of revenue in 2026, up from ~1% currently. - Overall revenue growth guidance between 20-30% year-on-year for FY26 and FY27, with margins stabilizing around 20-22%.

- Revenue growth of 20% to 30% year-on-year expected for FY '26 and similar growth anticipated for FY '27, bolstered by the commissioning of the new Jolva plant around Sep/Oct 2027 which will add new products and expand existing ones. - EBITDA margins are projected to stabilize between 20% to 22% by FY '27, improving due to better utilization and operational efficiencies, with FY '26 margins expected to be lower but trending upwards. - Existing plant capacity is expected to support revenues up to INR 850-900 crores without further capex. - New technology and plants, especially at Jolva, are expected to deliver gross margins akin to SDA products with operational benefits, potentially enhancing profitability. - SDA segment expected to grow about 25%-30% in the current year, driven by Euro 7 norms and new customer onboarding. - Semiconductor and electrolyte segments hold large potential but with gradual ramp-up, with semiconductor full-scale commercialization around 2028. - Overall, the company is optimistic about sustained profit growth driven by expanding capacities, improved product mix, and price stabilization.

- Tatva Chintan has onboarded two customers for the Structured Directing Agents (SDA) segment; one is in final contract signing and expected to start commercial supplies around August 2026. - The second customer's negotiations are ongoing, with commercialization anticipated in the second half of the current calendar year. - The Semiconductor Chemicals segment is in early stages; the company will execute its first plant trial order in the current quarter, with gradual full commercialization expected. - The new Jolva plant, targeted for commissioning around September-October 2027, is expected to support new agro products and expanded existing product lines. - Current SDA capacity utilization is around 55%, with enough capacity to handle growth without immediate capex. - Overall revenue potential from existing plants including PASC, SDA, electrolyte salts, and PTC is expected to reach INR 850-900 crores in about 2.5 to 3 years.